Celltrion Healthcare lands biosimilar deal in Brazil for 2nd straight year

The South Korean company also has high shares in other Latin American markets like Colombia and Chile

Celltrion's Remsima
Celltrion's Remsima
Min-Su Han 1
2023-01-11 10:28:07 hms@hankyung.com
Bio & Pharma

South Korea's Celltrion Healthcare Co. on Tuesday said that for the second straight year, it landed an order for infliximab, an antibody used to treat autoimmune disease, in Brazil, the largest pharmaceutical market in Latin America.

The company will supply in the first half of the year 342,000 vials of Remsima, a biosimilar of infliximab used to treat autoimmune ailments like rheumatoid arthritis, exclusively to the Brazilian federal government.

Celltrion Healthcare has focused on the core market of Brazil to bolster its presence in Latin America. Through an aggressive bidding strategy, the company has won bids for not only for Remsima but also other products such as Truxima, whose active ingredient is rituximab, and Herzuma, which uses trastuzumab.

Celltrion Healthcare has seen good performance in other Latin American countries, with Remsima's market shares in Colombia, Chile and Peru all exceeding 80%. The company's anti-cancer antibody biosimilars in Costa Rica and Ecuador command a market share of over 95%. 

Write to Min-Su Han at hms@hankyung.com
#Celltrion Healthcare #Brazil #biosimilar #Remsima #infliximab #Truxima #Herzuma #Latin American market

Celltrion develops oral antibody drug with US bio company

Celltrion develops oral antibody drug with US bio company

South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an oral antibody drug.RT-111 is an oral drug that uses ustekinumab, an ingredient in autoimmune disease treatment approved for use in the US under the

Celltrion acquires approval to sell Vegzelma in Canada

Celltrion acquires approval to sell Vegzelma in Canada

Celltrion's Vegzelma South Korea's biosimilar heavyweight Celltrion Inc. has obtained permission from the Canadian health ministry to sell anticancer biosimilar Vegzelma, the company said on Thursday.Vegzelma is a biosimilar to Avastin (ingredient name Bevacizumab) used to cure metastatic direc

Celltrion's Remsima receives approval in 100 countries in 10 years

Celltrion's Remsima receives approval in 100 countries in 10 years

Celltrion's Remsima South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) has been approved in more than 100 countries ten years after its first approval.Remsima is a TNF-alpha inhibitor that is used to

Celltrion applies for FDA approval for Remsima SC

Celltrion applies for FDA approval for Remsima SC

Celltrion's Remsima Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoimmune disease treatment.Remsima SC (infliximab) is a self-injectable drug developed as a subcutaneous injection formulation.A C
(* comment hide *}